Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piflufolastat F 18 PET/CT in metastatic clear cell renal cell carcinoma
NCT07084909Phase 3Withdrawn
- Sponsor
- Lantheus Holdings, Inc.
- Start
- Nov 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of piflufolastat f 18 (2 arms), sponsored by Lantheus Holdings, Inc. Primary endpoints: Establishing the optimum dose and timing window of piflufolastat F18 for detection of metastatic disease at Day 1 and Diagnostic performance of piflufolastat F 18 PET/CT to determine the presence or absence of metastatic disease at 6 months. Planned start Nov 2025; status: withdrawn.
02
Drugs
piflufolastat f 18
Beyond the preview
Go deeper on NCT07084909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07084909.